TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2018
Price : $35 *
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Tris Pharma
- 12 Nov 2018 Results presented in the Tris Pharma media release.
- 12 Nov 2018 According to a Tris Pharma media release, data from this trial was presented at the 2018 Neuroscience Education Institute (NEI) Congress.
- 09 Feb 2017 According to a Tris Pharma media release, were presented at the 2017 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History